Targeted therapies ease pruritus in prurigo nodularis, but indirect comparisons leave ranking uncertain
Moderate-to-severe prurigo nodularis remains one of dermatology’s most punishing itch disorders. The disease is driven by a neuroimmune loop in which scratching perpetuates inflammation, epidermal hyperplasia, fibrosis, and neural remodeling, making lesion control inseparable from itch control. Conventional treatment often falls short, which is why mechanism-based drugs aimed at type 2 inflammation, IL-31 signaling, oncostatin M receptor pathways, neurokinin signaling, or opioid receptors have drawn intense attention.
A systematic review and network meta-analysis now brings the randomized evidence into one comparative framework. Nine randomized controlled trials involving 1,597 patients with moderate-to-severe disease were eligible, and the analysis focused on itch response, Investigator’s Global Assessment response, and safety outcomes.
The central result is straightforward: nemolizumab, dupilumab, and vixarelimab improved itch response versus placebo. The active agents did not differ significantly from one another in indirect comparisons, which means the network supports efficacy over placebo but not reliable superiority among the treatments themselves.
Why these agents fit the biology of prurigo nodularis
The therapeutic logic is strong. PN is not just a skin eruption with itch attached; it is a chronic neuroimmune disorder in which cytokines and neural mediators reinforce each other. IL-4 and IL-13 contribute to type 2 inflammation, IL-31 is closely tied to itch signaling, and oncostatin M receptor activity links inflammation to tissue remodeling. By interfering with these pathways, targeted therapies can interrupt the cycle that keeps nodules inflamed and pruritus active.
That mechanistic fit helps explain why the trials converged on symptom relief even though they differed in design, dosing, background therapy, and outcome definitions. It also explains why some therapies may improve itch more consistently than lesion scores or broader global assessments: itch signaling can shift quickly when a relevant pathway is blocked, while nodular skin change may lag behind or require longer exposure.
Nemolizumab and vixarelimab also improved IGA response, supporting an effect beyond symptom relief alone. The network did not show statistically significant indirect differences among active therapies, so the comparative hierarchy remains unstable. In practical terms, the evidence supports use of these agents in appropriate patients, but it does not justify treating one as clearly superior on the basis of this network alone.
Safety signals were limited, with one clear exception
Safety data were reassuring overall. No active treatment significantly increased serious adverse events or discontinuation due to adverse events in the primary analyses. The exception was nemolizumab, which increased the risk of any adverse event.
That finding matters because targeted therapies for a chronic itch disorder are often used in patients already living with poor sleep, excoriated skin, and substantial treatment fatigue. Even a modest rise in minor adverse events can affect persistence with therapy, especially when symptom burden is high and expectations for rapid relief are substantial. The absence of a signal for serious adverse events or treatment discontinuation is still important, since it suggests the major limiting factor is not severe toxicity but tolerability at the level of everyday side effects.
The network was useful, but it cannot answer the head-to-head question
The analysis was built on a frequentist random-effects network meta-analysis with placebo as the common comparator. Risk ratios were used for itch and IGA responses, and odds ratios were used for safety outcomes. SUCRA rankings were treated only as supplementary descriptive measures, while certainty of evidence was assessed with CINeMA.
The design is elegant, but the inference is constrained by the trial structure. Every comparison between active therapies was indirect. No direct head-to-head randomized trials were available, which means the relative performance of nemolizumab versus dupilumab, or vixarelimab versus either of the others, cannot be established reliably from this network alone. Differences in eligibility criteria, baseline severity, itch instruments, dosing schedules, assessment time points, and background therapies all complicate indirect ranking.
The review tried to manage those differences carefully. Trial-specific severity thresholds were retained rather than forced into a single uniform cutoff. Safety analyses were restricted to a maximum observation period of 16 weeks to improve comparability, which also meant that 24-week dupilumab safety data from PRIME and PRIME2 were excluded from the primary safety networks. That conservative choice strengthens internal consistency, but it also narrows the evidence window.
Trial design differences shaped what could and could not be compared
The included studies were not interchangeable. Some trials required a high baseline itch burden plus a minimum number of nodules, while others enrolled patients with treatment-refractory generalized disease using different itch scales. One vixarelimab trial required at least 10 pruritic nodules and elevated Worst Itch Numeric Rating Scale thresholds at screening; a serlopitant study used a pruritus visual analog scale threshold instead. Those are not trivial differences. They influence who enters the trial, how severe the disease is at baseline, and how much room there is for improvement.
Background therapy also varied. In one nemolizumab trial, both the active and placebo arms received protocol-defined topical corticosteroids, making the estimate an incremental effect over shared background treatment rather than a pure monotherapy contrast. Multi-dose trials were collapsed into single drug-level nodes when needed, including the vixarelimab study with several dose arms. Those statistical decisions were necessary to preserve network connectivity, but they also reduce the granularity of dose-response interpretation.
What clinicians can take from the evidence right now
For patients with moderate-to-severe PN, the review supports a treatment conversation centered on mechanism-based therapy rather than repeated cycling through nonspecific approaches alone. The strongest comparative message is limited but clinically useful: several targeted agents improve itch over placebo, and the most consistent signals in this network came from nemolizumab, dupilumab, and vixarelimab.
The evidence does not justify claiming a winner among them. A clinician choosing among available therapies still has to account for access, comorbidities, prior treatment failure, labeling, tolerability, and the patient’s primary goal, whether that is itch reduction, lesion improvement, or both. In a disease where sleep loss and excoriation can dominate daily life, even small differences in onset, convenience, or adverse effects can matter at the bedside.
The remaining gap is not subtle: head-to-head randomized trials are still needed. Without them, indirect comparisons can guide discussion, but they cannot settle relative superiority or settle the question of which targeted therapy should be first choice for a given patient.